<DOC>
	<DOCNO>NCT01543620</DOCNO>
	<brief_summary>The project design test new biomarkers sensitive current standard detect injury proximal kidney tubule establish good criterion kidney safety concern may halt test drug human .</brief_summary>
	<brief_title>Prospective Observational Study Evaluate Biomarkers Aminoglycoside Nephrotoxicity Patients With Cystic Fibrosis</brief_title>
	<detailed_description>The goal clinical study advance acceptance new biomarkers design detect drug-induced kidney injury clinical trial . The Kidney Safety Project conduct four major medical center : - University Southern California - University Minnesota - MD Anderson Cancer Center - Dana-Farber Cancer Institute . Blood urine sample collect patient undergo treatment either cisplatin aminoglycosides , two different drug know cause injury proximal tubule kidney . Aminoglycosides common antibiotic drug take patient cystic fibrosis . Cisplatin common chemotherapy drug take patient head neck cancer . The Aminoglycoside Study Kidney Safety Project conduct University Southern California University Minnesota aim evaluate aminoglycoside induce acute kidney injury patient cystic fibrosis . The companion study , Cisplatin Study Kidney Safety Project , conduct MD Anderson Cancer Center Dana-Farber Cancer Institute aim evaluate cisplatin induced acute kidney injury patient head neck cancer . The data Kidney Safety Project , Aminoglycoside Study Cisplatin Study , combine determination best biomarkers predict drug-induced acute kidney injury .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Inclusion criterion : 1 . Males females â‰¥ 18 year age . 2 . Documentation CF diagnosis evidence one clinical feature consistent CF phenotype one follow criterion : Sweat chloride great equal 60 mEq/L quantitative pilocarpine iontophoresis test . Two wellcharacterized mutation cystic fibrosis transmembrane conductance regulator ( CFTR ) gene ; Abnormal nasal potential difference . 3 . Hospitalized initiated systemic antibiotic therapy treatment acute pulmonary exacerbation . 4 . Willingness ability comply study procedure study restriction . 5 . Ability provide write informed consent . Exclusion criterion : 1 . Chronic kidney disease define microalbuminuria ( &gt; 30 mcg/mg creatinine ) eGFR &lt; 60 mL/min/1.73m2 . 2 . Receiving medication know alter tubular secretion creatinine ( e.g . trimethoprim , cimetidine ) . 3 . Hospitalized treatment acute pulmonary exacerbation receive intravenous aminoglycoside antibiotic within 3months study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>kidney safety</keyword>
	<keyword>biomarkers</keyword>
	<keyword>serum creatinine</keyword>
	<keyword>BUN</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>renal injury</keyword>
	<keyword>drug induce acute kidney injury</keyword>
	<keyword>aminoglycoside</keyword>
	<keyword>cisplatin</keyword>
	<keyword>nephrotoxicity</keyword>
	<keyword>biomarker qualification</keyword>
</DOC>